%0 Journal Article
%A Schadendorf, Dirk
%T COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma.
%J Future oncology
%V 21
%N 21
%@ 1479-6694
%C London
%I Taylor & Francis
%M DKFZ-2025-01535
%P 2701-2703
%D 2025
%Z 2025 Sep;21(21):2701-2703 / MULTIMEDIA ARTICLE
%X This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.
%K 7-year update (Other)
%K BRAF V600 (Other)
%K COLUMBUS (Other)
%K Lead author commentary (Other)
%K binimetinib (Other)
%K encorafenib (Other)
%K melanoma (Other)
%K vemurafenib (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40705373
%R 10.1080/14796694.2025.2536459
%U https://inrepo02.dkfz.de/record/303116